TREatment of degeNerative and Neoplastic Diseases With Rituximab

Summary

This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of PBO-326 (Rituximab) and Mabthera (Rituximab) in combination with CHOP in previously untreated patients with diffuse B cells Non Hodgkin lymphoma.

Timeline

Start

2010-10

Primary completion

2011-09

Completion

2011-10

Drugs

Indications